Abbott Laboratories (NYSE:ABT) is scheduled to announce its earnings results before the market opens on Wednesday, April 17th. Analysts expect the company to announce earnings of $0.61 per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.
Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Wednesday, January 23rd. The healthcare product maker reported $0.81 EPS for the quarter, meeting analysts’ consensus estimates of $0.81. Abbott Laboratories had a net margin of 7.74% and a return on equity of 16.55%. The company had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.82 billion. During the same period last year, the business earned $0.74 earnings per share. Abbott Laboratories’s revenue was up 2.3% compared to the same quarter last year. On average, analysts expect Abbott Laboratories to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.
ABT stock opened at $77.50 on Tuesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.62 and a quick ratio of 1.20. Abbott Laboratories has a 12 month low of $56.81 and a 12 month high of $80.74. The company has a market capitalization of $137.90 billion, a PE ratio of 26.91, a PEG ratio of 2.09 and a beta of 1.13.
ABT has been the subject of several research analyst reports. Credit Suisse Group initiated coverage on shares of Abbott Laboratories in a research report on Monday, December 17th. They set an “outperform” rating and a $82.00 target price for the company. Citigroup lowered shares of Abbott Laboratories from a “neutral” rating to a “sell” rating and dropped their target price for the company from $72.00 to $68.00 in a research report on Wednesday, January 2nd. Morgan Stanley lifted their target price on shares of Abbott Laboratories from $82.00 to $85.00 and gave the company an “overweight” rating in a research report on Wednesday, January 2nd. Gabelli reiterated a “buy” rating on shares of Abbott Laboratories in a research report on Wednesday, January 2nd. Finally, BTIG Research reiterated a “hold” rating on shares of Abbott Laboratories in a research report on Thursday, January 24th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and fifteen have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $80.48.
In other news, insider Joseph J. Manning sold 1,223 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $78.00, for a total value of $95,394.00. Following the completion of the sale, the insider now directly owns 61,324 shares in the company, valued at approximately $4,783,272. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Jaime Contreras sold 177,457 shares of the business’s stock in a transaction that occurred on Wednesday, January 30th. The stock was sold at an average price of $70.00, for a total transaction of $12,421,990.00. Following the completion of the sale, the insider now owns 100,985 shares of the company’s stock, valued at $7,068,950. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 280,021 shares of company stock valued at $20,485,856. Company insiders own 0.70% of the company’s stock.
Abbott Laboratories Company Profile
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.
Read More: Gross Domestic Product (GDP)
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.